Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

Table 1

Laboratory values.

	= 0; (Start BTZ)	= +3 w; (Time of renal biopsy)	= +4 m; (1 m after stop of BTZ)	= +18 m; (Rechallenge BTZ)	= +19  m; (Start dialysis)	= +22 m; (After stop of dialysis)
Hb (g/dL)	9.2	7.5	9.2	9.8	7.9	8.7
WBC (×10^9/L)	2.43	1.37	2.19	2.63	3.07	2.37
Platelets (×10^9/L)	128	119	77	34	14	42
Schistocytes (/1000 RBC)	<3	4–7	<3	<5	40–50	<5
Haptoglobin (g/L)	—	<0.1	3.08	1.33	<0.1	0.9
LDH (U/L)	156	218	102	468	419	237
Creatinine (mg/dL)	1.35	2.65	2.04	3.00	7.49	2.89
Ureum (mg/dL)	39	70	33	80	147	97
Proteinuria (g/24 h)	1.2	0.6	1.52	1.37	2.69	0.6
Hematuria (RBC/µL)	258	2079	661	—	Hematuria	Hematuria
Pyuria (WBC/µL)	14	24	3	—	56	4
IgG (g/L)	88.2	—	24.3	16	10.7	—

BTZ: bortezomib; w: weeks; m: months; —: not available.